Goldman Sachs Group »

Kalaris Therapeutics shares owned by Goldman Sachs Group

Quarter-by-quarter ownership of Kalaris Therapeutics (KLRS) shares owned by Goldman Sachs Group from 13F filings

Historical chart of Goldman Sachs Group investment in Kalaris Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Kalaris Therapeutics held by Goldman Sachs Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Kalaris Therapeutics by Goldman Sachs Group

Quarter filed Position value Share count Share price at filing
2025-09-30 $130k 23k 5.78

More positions owned by Goldman Sachs Group

Nvidia Corporation CMN (NVDA)
Spdr S&p 500 Etf Tr CMN (SPY)
Microsoft Corp CMN (MSFT)
Apple CMN (AAPL)
Invesco Qqq Tr CMN Put Option (QQQ)
Tesla CMN (TSLA)
Amazon CMN (AMZN)
Meta Platforms CMN (META)
Alphabet CMN (GOOGL)
Broadcom CMN (AVGO)
Ishares Tr CMN (IVV)
Ishares Tr CMN Put Option (IWM)
Vanguard Index Fds CMN (VOO)
Ishares Tr CMN Put Option (HYG)
Jpmorgan Chase & Co. CMN (JPM)

View all positions for Goldman Sachs Group

Top funds holding Kalaris Therapeutics

Samsara BioCapital
Tang Capital Management
Siren
Woodline Partners
Vanguard Group
Renaissance Technologies
Redmile Group
Geode Capital Management
BlackRock
Squarepoint Ops
Fortis Capital Advisors
Belpointe Asset Management
Millennium Management
State Street Corporation
Bridgeway Capital Management

View all funds holding Kalaris Therapeutics